Huifen Chen

11PUBLICATIONS
18CO-AUTHORS
Molecular targetsNeural engineeringGene and molecular therapyToxicology (incl. clinical toxicology)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 18, 2026
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models.

|Oct 30, 2025
Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases.

Snahel Patel, Huifen Chen, Eugene Varfolomeev

|Mar 03, 2024
Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease.

Jack A Terrett, Justin Q Ly, Paula Katavolos

|Jan 05, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.

Michael Berlin, Jennifer Cantley, Mark Bookbinder

|Nov 15, 2021
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors.

Dennis X Hu, Snahel Patel, Huifen Chen

|Aug 20, 2021
A Retrospective Look at the Impact of Binding Site Environment on the Optimization of TRPA1 Antagonists.

Elisia Villemure, Jack A Terrett, Robin Larouche-Gauthier

Pageof 2

Frequent Collaborators

4 joint publications

Jack A Terrett

3 joint publications

Peter S Dragovich

3 joint publications

Christopher M Rose

2 joint publications

Adam R Johnson